Garvin Joins DCI as Director of Research Development-Clinical Research
Shanta Laurie Garvin MHSA, MPA, CRA, has joined Duke Cancer Institute as director of Research Development-Clinical Research. (effective June 1, 2021)
In this new role Garvin will lead and manage activities to enhance processes, prepare for continued growth, assure staff development, expand communication with investigators, identify and assist in developing areas for growth in clinical research funding, ensure that use of new tools and best practices are optimized, and contribute to advancing the recognition of the work of the DCI through targeted communications and outreach.
"Shanta is a persuasive communicator and team-oriented leader who focuses on the big picture not to exclude or minimize how systems work together in order to establish and measure goals to reach desired outcomes," said Karen Kharasch, senior director of Research Strategy & Operations at DCI.
Garvin has 20 years of experience in research administration — grants, contracts, research billing — in both academic and healthcare settings, including Savannah State University, Emory University, Children’s Healthcare of Atlanta and Vanderbilt University Medical Center. She has a Bachelor’s of Science in Political Science, a Masters in Public Administration- Policy Management, and a Masters- Health Services Administration.
As a Certified Research Administrator, Garvin's expertise lies in her comprehensive knowledge of best practices in sponsored research administration; knowledge of and application of institutional policies and their impact on daily operations; and establishing and maintaining relationships with stakeholders.
"She is a leader who encourages and supports teamwork, high level customer service, as well as individual professional growth and development. Her career has provided a wide array of opportunities with increased levels of duties, responsibilities and authority," said Kharasch. "She brings to us a wealth of knowledge, skills, and abilities and an open mind to learn and enhance the operations of clinical research administration within DCI."